Hartmann2016 - Blood coagulation model for simulating anticoagulants
Model Identifier
MODEL1807180004
Short description
Mathematical model of blood coagulation. Reused Wajima2009 model with modifications to reactions 27 (formation of Va:Xa complex), 32 (Xa inhibition by TFPI) and 45 (Xa inhibition by TFPI-Heparin complex) as described in publication equations 2,3 and 4. Publication lists parameter sets to simulate Rivaroxaban, VKA and Enoxaparin (supplementary files).
Format
SBML
(L2V4)
Related Publication
-
Quantitative Systems Pharmacology Model to Predict the Effects of Commonly Used Anticoagulants on the Human Coagulation Network.
- Hartmann S, Biliouris K, Lesko LJ, Nowak-Göttl U, Trame MN
- CPT: pharmacometrics & systems pharmacology , 10/ 2016 , Volume 5 , Issue 10 , pages: 554-564 , PubMed ID: 27647667
- Center for Pharmacometrics and Systems Pharmacology, Department of Pharmaceutics, University of Florida, Orlando, Florida, USA.
- Warfarin is the anticoagulant of choice for venous thromboembolism (VTE) treatment, although its suppression of the endogenous clot-dissolution complex APC:PS may ultimately lead to longer time-to-clot dissolution profiles, resulting in increased risk of re-thrombosis. This detrimental effect might not occur during VTE treatment using other anticoagulants, such as rivaroxaban or enoxaparin, given their different mechanisms of action within the coagulation network. A quantitative systems pharmacology model was developed describing the coagulation network to monitor clotting factor levels under warfarin, enoxaparin, and rivaroxaban treatment. The model allowed for estimation of all factor rate constants and production rates. Predictions of individual coagulation factor time courses under steady-state warfarin, enoxaparin, and rivaroxaban treatment reflected the suppression of protein C and protein S under warfarin compared to rivaroxaban and enoxaparin. The model may be used as a tool during clinical practice to predict effects of anticoagulants on individual clotting factor time courses and optimize antithrombotic therapy.
Contributors
Submitter of the first revision: Matthew Roberts
Submitter of this revision: Matthew Roberts
Modellers: Matthew Roberts
Submitter of this revision: Matthew Roberts
Modellers: Matthew Roberts
Metadata information
hasPart (1 statement)
isDescribedBy (1 statement)
hasTaxon (1 statement)
isVersionOf (1 statement)
hasProperty (1 statement)
isDescribedBy (1 statement)
hasTaxon (1 statement)
isVersionOf (1 statement)
hasProperty (1 statement)
Curation status
Non-curated
Tags
Connected external resources
SBGN view in Newt Editor
| Name | Description | Size | Actions |
|---|---|---|---|
Model files |
|||
| Hartmann2016.xml | SBML L2V4 representation of Hartmann2016 - Blood coagulation model for simulating anticoagulants | 281.13 KB | Preview | Download |
Additional files |
|||
| Hartmann2016.cps | Model XML file. Reused Wajima2009 model. Reactions 27, 32 and 45 were modified to include the effect of rivaroxaban as in equations 2, 3 and 4 of the publication. Attempted to reproduce figure 4. | 420.13 KB | Preview | Download |
- Model originally submitted by : Matthew Roberts
- Submitted: Jul 18, 2018 12:39:29 PM
- Last Modified: Jul 18, 2018 12:39:29 PM
Revisions
-
Version: 2
- Submitted on: Jul 18, 2018 12:39:29 PM
- Submitted by: Matthew Roberts
- With comment: Edited model metadata online.